Merck reports new positive outcomes for KEYTRUDA in stage 3 Melanoma trial

This article was originally published here

Late-breaking, first-time study results showed that with 3.5 years of follow-up, adjuvant KEYTRUDA met the key secondary endpoint of distant metastasis-free survival (DMFS), reducing the risk of distant

The post Merck reports new positive outcomes for KEYTRUDA in stage 3 Melanoma trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply